HuGE Literature Finder
|
||
Records 1-100
|
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
British journal of clinical pharmacology 2019 Apr . Helin Tuukka A, Joutsi-Korhonen Lotta, Asmundela Heidi, Niemi Mikko, Orpana Arto, Lassila Riit |
|
Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes.
Medicine 2019 Feb 98 (6): e14365. Sr Kalpana, G Bharath, Jain Simran, Moorthy Nagaraja, Manjunath Satvic C, Christopher Ri |
|
Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Indian heart journal 2018 Dec 70 Suppl 3 S13-S19. Biswas Mansij, Bendkhale Shital R, Deshpande Siddharth P, Thaker Saket J, Kulkarni Dwarkanath V, Bhatia Shobna J, Rajadhyaksha Anjali G, Gogtay Nithya J, Thatte Urmila |
|
Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population.
Indian heart journal 2018 Dec 70 Suppl 3 S110-S115. Harikrishnan S, Koshy Linda, Subramanian Ram, Sanjay G, Vineeth C P, Nair A Jayakumaran, Nair G M, Sudhakaran P |
|
Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism.
The pharmacogenomics journal 2018 Aug . Kabalak P?nar Ak?n, Sava? ?smail, Akar Nejat, Demir Nalan, E?in Yon |
|
The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2018 Apr 34 (2): 328-336. Bedewy Ahmed M L, Showeta Salah, Mostafa Mostafa Hasan, Kandil Lamia Sae |
|
Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Vascular pharmacology 2018 Feb . Bryk Agata Hanna, Wypasek Ewa, Plens Krzysztof, Awsiuk Magdalena, Undas Anet |
|
Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
European journal of clinical pharmacology 2018 Feb . Ajmi Marwa, Omezzine Asma, Achour Slim, Amor Dorra, Hamdouni Haithem, Ismaïl Fatma Ben Fredj, Rejeb Nabila Ben, Kechrid Chedia Laouani, Boughzela Essia, Bouslama A |
|
VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
Future cardiology 2018 Jan 14 (1): 15-26. Mili Fatima Donia, Allen Tenecia, Wadell Paula Weinstein, Hooper W Craig, Staercke Christine De, Bean Christopher J, Lally Cathy, Austin Harland, Wenger Nanette |
|
Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V.
Journal of thrombosis and thrombolysis 2017 Sep . Abdi Abshir Ali, Osman Abdimaj |
|
Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Journal of thrombosis and haemostasis : JTH 2017 Aug . Nagler M, Angelillo-Scherrer A, Méan M, Limacher A, Abbal C, Righini M, Beer J H, Osterwalder J, Frauchiger B, Aschwanden M, Matter C M, Kucher N, Cornuz J, Banyai M, Husmann M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky |
|
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017 Apr . Park Yun Kyung, Lee Mi Ji, Kim Jae Ha, Lee Jin Soo, Park Rae Woong, Kim Gyeong-Moon, Chung Chin-Sang, Lee Kwang Ho, Kim June Soo, Lee Soo-Youn, Bang Oh You |
|
Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing 2017 Mar 35 (1): 27-30. Schapkaitz Elise, Sithole Johan |
|
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Journal of thrombosis and haemostasis : JTH 2017 Jan . Hernandez Wenndy, Gamazon Eric R, Aquino-Michaels Keston, Smithberger Erin, O'Brien Travis J, Harralson Arthur F, Tuck Matthew, Barbour April, Cavallari Larisa H, Perera Minoli |
|
Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population.
Scientific reports 2017 12 7 (1): 17379. Cai Liang-Liang, Huang Wen-Qing, Su Zhi-Ying, Ye Hui-Ming, Wang Lian-Sheng, Wu Yuan, Zhang Zhong-Ying, Zhang Wei, Tzeng Chi-Me |
|
Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
International journal of clinical pharmacology and therapeutics 2017 02 55 (2): 126-132. Chen Weirong, Wu Luhua, Liu Xin, Shen Yue, Liang Yan, Zhu Jun, Tan Huiqiong, Yang Yanmin, Liu Qun, Wang Mingsheng, Liu Lisheng, Wang Xing |
|
The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
Blood cells, molecules & diseases 2016 Dec . Nowak-Göttl U, Dietrich K, Kruempel A, Geisen C, Mitchell L |
|
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
Medicine 2016 Dec 95 (52): e5451. Misasi Silvia, Martini Giuliana, Paoletti Oriana, Calza Stefano, Scovoli Giovanni, Marengoni Alessandra, Testa Sophie, Caimi Luigi, Marchina Eleono |
|
Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices†.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2016 Mar . Brehm Kerstin, Krumnau Oliver, Heilmann Claudia, Beyersdorf Friedhe |
|
[FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].
Georgian medical news 2016 Jan (250): 46-51. Jokhadze T, Kakauridze N, Buadze T, Gaiozishvili M, Lezhava |
|
High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Drug discoveries & therapeutics 2016 9 (6): 404-10. Sehgal Tushar, Hira Jasbir Kaur, Ahluwalia Jasmina, Das Reena, Vijayvergiya Rajesh, Rana Sandip Singh, Varma Neel |
|
Pharmacogenomic Testing and Warfarin Management.
Oncology nursing forum 2015 Sep 42 (5): 563-5. Maluso Andr |
|
Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes.
Thrombosis research 2015 Aug 136 (2): 367-70. Ciccacci Cinzia, Rufini Sara, Politi Cristina, Novelli Giuseppe, Forte Vittorio, Borgiani Pao |
|
Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves.
Cardiovascular therapeutics 2015 Jul . An Sook Hee, Chang Byung Chul, Lee Kyung Eun, Gwak Hye S |
|
Race influences warfarin dose changes associated with genetic factors.
Blood 2015 Jul 126 (4): 539-45. Limdi Nita A, Brown Todd M, Yan Qi, Thigpen Jonathan L, Shendre Aditi, Liu Nianjun, Hill Charles E, Arnett Donna K, Beasley T Ma |
|
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2015 Jun 98 (6): 549-54. Sermsathanasawadi Nuttawut, Sritongsathian Chukij, Pongrattanaman Nunthapol, Praditsuktavorn Banjerd, Hongku Kiattisak, Wongwanit Chumpol, Ruangsetakit Chanean, Chinsakchai Khamin, Mutirangura Pramook, Poungvarin Narav |
|
VKORC1 -1639 G>A Polymorphism in Romanian Patients With Deep Vein Thrombosis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2015 May . Vesa ?tefan Cristian, Trifa Adrian Pavel, Cri?an Sorin, Buzoianu Anca Da |
|
[Association of allelic polymorphisms of genes matrix Gla-protein system with ischemic atherothrombotic stroke].
Fiziolohichny? zhurnal (Kiev, Ukraine : 1994) 2015 61 (1): 19-27. Garbuzova V Yu, Stroy D A, Dosenko V E, Dubovyk Ye I, Borodenko A O, Shimko K A, Obukhova O A, Ataman O |
|
[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
Kardiologiia 2015 55 (4): 57-60. Kokh N V, Slepukhina A A, Tsvetovskaya G A, Lifshits G |
|
[HAS-BLED and HEMORR2HAGES Scales in Assessment of Bleeding Risk in Patients on Long-Term Warfarin Therapy].
Kardiologiia 2015 55 (9): 50-6. Moreva O V, Kropacheva E S, Panchenko E P, Dobrovolsky A B, Zemlyanskaya O A, Donnikov A E, Titaeva E V, Guskova I |
|
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
Molecular diagnosis & therapy 2014 Dec 18 (6): 675-83. de Oliveira Almeida Vanessa Cristina, Ribeiro Daniel Dias, Gomes Karina Braga, Godard Ana Lúcia Brunial |
|
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Pharmacogenetics and genomics 2014 Oct 24 (10): 501-13. Jiménez-Varo Enrique, Cañadas-Garre Marisa, Gutiérrez-Pimentel María J, Calleja-Hernández Miguel |
|
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
Journal of thrombosis and haemostasis : JTH 2014 Sep 12 (9): 1480-7. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci P |
|
Pharmacogenetics role in the safety of acenocoumarol therapy.
Thrombosis and haemostasis 2014 Sep 112 (3): 522-36. Jiménez-Varo E, Cañadas-Garre M, Henriques C I, Pinheiro A M, Gutiérrez-Pimentel M J, Calleja-Hernández M |
|
The impact of VKORC1-1639G?>?A genetic polymorphism upon warfarin dose requirement in different ethnic populations.
Current medical research and opinion 2014 Aug 30 (8): 1505-11. Jin Bo, Hong Yong, Zhu Jun, Li Yong, Shi Hai-Mi |
|
Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Irish journal of medical science 2014 Jun 183 (2): 161-72. Bazan N S, Sabry N A, Rizk A, Mokhtar S, Badary O |
|
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2014 Jun . Azzam Hanan, Elwakeel Hossam, Awad Ibrahim, El-Farahaty Reham, El-Gilany Abdel-Hady, El-Sharawy Sola |
|
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
European journal of clinical pharmacology 2014 Jan 70 (1): 47-56. Krishna Kumar Dhakchinamoorthi, Shewade Deepak Gopal, Loriot Marie-Anne, Beaune Philippe, Balachander Jayaraman, Sai Chandran B V, Adithan Chandrasekar |
|
A randomized trial of genotype-guided dosing of warfarin.
The New England journal of medicine 2013 Dec 369 (24): 2294-303. Pirmohamed Munir, Burnside Girvan, Eriksson Niclas, Jorgensen Andrea L, Toh Cheng Hock, Nicholson Toby, Kesteven Patrick, Christersson Christina, Wahlström Bengt, Stafberg Christina, Zhang J Eunice, Leathart Julian B, Kohnke Hugo, Maitland-van der Zee Anke H, Williamson Paula R, Daly Ann K, Avery Peter, Kamali Farhad, Wadelius Mia, |
|
Role of the vitamin K epoxide reductase complex subunit 1 (VKORC1) -1639G>A gene polymorphism in patients with retinal vein occlusion.
Current eye research 2013 Dec 38 (12): 1278-82. Weger Martin, Steinbrugger Iris, Renner Wilfried, Pöschl Eva Maria, Brockmann Tobias, Rabensteiner Dieter Franz, El-Shabrawi Yosuf, Haas Ant |
|
An acenocoumarol dose algorithm based on a South-Eastern European population.
European journal of clinical pharmacology 2013 Nov 69 (11): 1901-7. Pop Tudor Radu, Vesa ?tefan Cristian, Trifa Adrian Pavel, Cri?an Sorin, Buzoianu Anca Da |
|
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Pharmacogenetics and genomics 2013 Nov 23 (11): 611-8. Wolkanin-Bartnik Jolanta, Pogorzelska Hanna, Szperl Ma?gorzata, Bartnik Aleksandra, Koziarek Jacek, Bilinska Zofia |
|
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2013 Aug 44 (2): 309-14; discussion 314-5. Brehm Kerstin, Schack Jenny, Heilmann Claudia, Blanke Philipp, Geissler Hans Joachim, Beyersdorf Friedhe |
|
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?
Clinical medicine & research 2013 Jun 11 (2): 73-9. Glurich Ingrid, Berg Richard L, Burmester James |
|
Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
European journal of pharmacology 2013 Jun 710 (1-3): 80-4. Gaikwad Tejasvita, Ghosh Kanjaksha, Kulkarni Bipin, Kulkarni Vrinda, Ross Cecil, Shetty Shrima |
|
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
Thrombosis and haemostasis 2013 Jun 109 (6): 1045-50. Shahin Mohamed Hossam A, Cavallari Larisa H, Perera Minoli A, Khalifa Sherief I, Misher Anne, Langaee Taimour, Patel Shitalben, Perry Kimberly, Meltzer David O, McLeod Howard L, Johnson Julie |
|
Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians.
Arthritis and rheumatism 2013 Jan 65 (1): 211-5. Kaiser Rachel, Taylor Kimberly E, Deng Yun, Zhao Jian, Li Yonghong, Nititham Joanne, Chang Monica, Catanese Joseph, Begovich Ann B, Brown Elizabeth E, Edberg Jeffrey C, McGwin Gerald, Alarcón Graciela S, Ramsey-Goldman Rosalind, Reveille John D, Vila Luis M, Petri Michelle, Kimberly Robert P, Feng Xuebing, Sun Lingyun, Shen Nan, Li Wei, Lu Jian-Xin, Wakeland Edward K, Li Quan-Zhen, Yang Wanling, Lau Yu-Lung, Liu Fei-Lan, Chang Deh-Ming, Yu Chack-Yung, Song Yeong W, Tsao Betty P, Criswell Lindsey A, |
|
VKORC1 C1173T and VKORC1 G-1639A Gene Polymorphisms in Turkish Behçet's Patients with Ocular and Non-ocular Involvement.
Ophthalmic genetics 2013 Jan . Demir HD, Ortak H, Sahin S, Ate? O, Benli I, Inan?r A |
|
[Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2013 133 (10): 1079-85. Hayashi Hide |
|
Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Trials 2012 Dec 13 (1): 1. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL |
|
Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
The Journal of the Association of Physicians of India 2012 Dec 60 34-8. Shalia Kavita K, Doshi Shripal M, Parikh Suhas, Pawar Poonam P, Divekar Siddhi S, Varma Sandeep P, Mehta Rachna, Doctor Tasneem, Shah Vinod K, Saranath |
|
Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Pathologie-biologie 2012 Nov . Smires FZ, Habbal R, Moreau C, Assaidi A, Loriot MA, Nadifi S |
|
Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.
Journal of thrombosis and thrombolysis 2012 Nov 34 (4): 506-12. Giansante Carlo, Fiotti Nicola, Altamura Nicola, Pitacco Paola, Consoloni Lara, Scardi Sabino, Mazzone Carmine, Grassi Gabriele, Pandullo Claudio, Di Lenarda Andr |
|
CYP2C9 and VKORC1 Gene Polymorphism is Inessential for Bleeding Development under Conditions of Oral Application of Anticoagulant Acenocoumarol in Russian Patients at High Risk of Thromboembolic Complications.
Bulletin of experimental biology and medicine 2012 Oct 153 (6): 6. Sychev DV, Ignatyev IV, Emelyanov NV, Milovanova VV, Kossovskaya AV, Kukes IV, Tashenova AI, Kukes VG |
|
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Journal of clinical pharmacy and therapeutics 2012 Oct 37 (5): 594-8. Smires F Z, Moreau C, Habbal R, Siguret V, Fadili S, Golmard J L, Assaidi A, Beaune P, Loriot M A, Nadifi |
|
The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.
Molecular biology reports 2012 Oct . Silan C, Dogan OT, Silan F, Kukulguven FM, Asgun HF, Ozdemir S, Uludag A, Atik S, Gungor B, Akdur S, Aksulu HE, Ozdemir O |
|
Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Journal of human genetics 2012 Oct 57 (10): 665-9. Pathare Anil, Al Khabori Murtadha, Alkindi Salam, Al Zadjali Shoaib, Misquith Rhea, Khan Hammad, Lapoumeroulie Claudine, Paldi Andras, Krishnamoorthy Rajagop |
|
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Thrombosis and haemostasis 2012 Jun 107 (6): 1083-91. Wei Meng, Ye Fei, Xie Dujiang, Zhu Yubing, Zhu Junrong, Tao Yifu, Yu Fe |
|
White blood cells contribute to patient-specific warfarin dose for Han Chinese.
Chinese medical journal 2012 Jun 125 (11): 1960-3. Zhu Jin, Zheng Wen-Jie, Zhang Wei-Juan, Wang He-Yao, Wang Ch |
|
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
Journal of thrombosis and haemostasis : JTH 2012 May 10 (5): 767-72. van Schie R M F, Babajeff A M V, Schalekamp T, Wessels J A M, le Cessie S, de Boer A, van der Meer F J M, van Meegen E, Verhoef T I, Rosendaal F R, Maitland-van der Zee A H, |
|
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
European journal of clinical pharmacology 2012 May 68 (5): 617-27. Mlynarsky Liat, Bejarano-Achache Idit, Muszkat Mordechai, Caraco Yose |
|
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Journal of thrombosis and haemostasis : JTH 2012 Apr 10 (4): 606-14. Verhoef T I, Redekop W K, Buikema M M, Schalekamp T, Van Der Meer F J M, Le Cessie S, Wessels J A M, Van Schie R M F, De Boer A, Teichert M, Visser L E, Maitland-Van Der Zee A H, |
|
Multivariate analysis of the relation between diet and warfarin dose.
European journal of clinical pharmacology 2012 Mar 68 (3): 321-8. Rasmussen Morten Arendt, Skov Jane, Bladbjerg Else-Marie, Sidelmann Johannes J, Vamosi Marianne, Jespersen Jørg |
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
Pharmacogenomics 2012 Feb 13 (3): 309-21. Zhang Wei, Zhang Wei-Juan, Zhu Jin, Kong Fan-Cui, Li Yan-Yan, Wang He-Yao, Yang Yuan-Hua, Wang Ch |
|
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
PloS one 2012 7 (7): e41360. Borobia Alberto M, Lubomirov Rubin, Ramírez Elena, Lorenzo Alicia, Campos Armando, Muñoz-Romo Raul, Fernández-Capitán Carmen, Frías Jesús, Carcas Antonio |
|
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Journal of clinical pharmacology 2011 Oct 51 (10): 1418-28. Esmerian Maria O, Mitri Zahi, Habbal Mohammad-Zuheir, Geryess Eddy, Zaatari Ghazi, Alam Samir, Skouri Hadi N, Mahfouz Rami A, Taher Ali, Zgheib Nathalie |
|
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
Thrombosis research 2011 Jun 127 (6): 595-9. Ames Paul R J, Margaglione Maurizio, Ciampa Antonio, Colaizzo Donatella, Ferrara Felicetto, Iannaccone Luigi, Vincenzobrancacci |
|
[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
Vestnik Rossi?sko? akademii meditsinskikh nauk / Rossi?skaia akademiia meditsinskikh nauk 2011 (3): 3. Authors are not available |
|
Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
Journal of thrombosis and haemostasis : JTH 2011 Apr 9 (4): 711-8. Moreau C, Pautas E, Gouin-Thibault I, Golmard J-L, Mahé I, Mulot C, Loriot M-A, Siguret |
|
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Journal of thrombosis and haemostasis : JTH 2011 Jan 9 (1): 109-18. Watzka M, Geisen C, Bevans C G, Sittinger K, Spohn G, Rost S, Seifried E, Müller C R, Oldenburg |
|
[Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Terapevticheski? arkhiv 2011 83 (6): 59-65. Vorob'eva N M, Panchenko E P, Dobrovol'ski? A B, Titaeva E V, Khasanova Z B, Konovalova N V, Postnov A Iu, Kirienko A |
|
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
BMC medical genetics 2011 12 80. Suriapranata Ivet M, Tjong Wen Ye, Wang Tingliang, Utama Andi, Raharjo Sunu B, Yuniadi Yoga, Tai Susan |
|
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
Annals of clinical and laboratory science 2011 41 (3): 229-35. Moon Hee-Won, Noh Jaekwang, Yun Yeo-Min, Kim Hahn Young, Yun Ik Jin, Song Junghan, Kim Jin |
|
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Blood 2010 Dec 116 (26): 6101-5. Nowak-Göttl Ulrike, Dietrich Kevin, Schaffranek Daria, Eldin Noha Sharaf, Yasui Yutaka, Geisen Christof, Mitchell Lesley |
|
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders.
Annals of hematology 2010 Nov 89 (11): 1147-54. Antón Ana I, González-Conejero Rocio, Roldán Vanessa, Quiroga Teresa, Sánchez-Vega Beatriz, Corral Javier, Vicente Vicente, Mezzano Die |
|
Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Thrombosis research 2010 Sep 126 (3): e235-7. Le Cam-Duchez Véronique, Frétigny Mathilde, Cailleux Nicole, Gandelin Catherine, Lévesque Hervé, Borg Jeanne-Yvon |
|
The association of protein S Tokushima-K196E with a risk of deep vein thrombosis.
International journal of hematology 2010 Sep 92 (2): 302-5. Ikejiri Makoto, Wada Hideo, Sakamoto Yuko, Ito Naohiko, Nishioka Junji, Nakatani Kaname, Tsuji Akihiro, Yamada Norikazu, Nakamura Mashio, Ito Masaaki, Nobori Tsuto |
|
VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis.
Thrombosis research 2010 Aug 126 (2): e134-6. Pasmant Eric, de Beauvoir Charlotte, Plessier Aurélie, Labreuche Julien, Bezeaud Ann |
|
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Thrombosis research 2010 Jun 125 (6): e259-64. Wells P S, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard |
|
Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
Therapeutic drug monitoring 2010 Jun 32 (3): 338-45. McMillin Gwendolyn A, Melis Roberta, Wilson Andrew, Strong Michael B, Wanner Nathan A, Vinik Russell G, Peters Christopher L, Pendleton Robert |
|
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
Journal of the American College of Cardiology 2010 Jun 55 (25): 2804-12. Epstein Robert S, Moyer Thomas P, Aubert Ronald E, O Kane Dennis J, Xia Fang, Verbrugge Robert R, Gage Brian F, Teagarden J Russe |
|
Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 Feb 16 (1): 83-90. Palacio Lina, Falla Diana, Tobon Ignacio, Mejia Fernando, Lewis John E, Martinez Ariel F, Arcos-Burgos Mauricio, Camargo Mauric |
|
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
Journal of thrombosis and haemostasis : JTH 2010 Jan 8 (1): 95-100. Ferder N S, Eby C S, Deych E, Harris J K, Ridker P M, Milligan P E, Goldhaber S Z, King C R, Giri T, McLeod H L, Glynn R J, Gage B |
|
[Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study].
Kardiologiia 2010 50 (5): 42-6. Sychev D A, Antonov I M, Ignat'ev I V, Naumova Iu V, Dmitriev V A, Kropacheva E S, Dobrovol'ski? O B, Panchenko E P, Tashenova I A, Kukes V |
|
[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
Terapevticheski? arkhiv 2010 82 (5): 33-9. Kondrat'eva L V, Patrusheva N L, Patrushev L I, Aleksandrova E N, Kovalenko T F, Ostriakova E V, Reshetniak T |
|
Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).
Thrombosis journal 2009 7 . Branco CC, Pereirinha T, Cabral R, Pacheco PR, Mota-Vieira L |
|
VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.
Clinical orthopaedics and related research 2009 Jul 467 (7): 1773-80. González Della Valle Alejandro, Khakharia Saurabh, Glueck Charles J, Taveras Nicole, Wang Ping, Fontaine Robert N, Salvati Eduardo |
|
Prothrombotic genetic variants and atherosclerosis in patients with cerebral ischemia of arterial origin.
Atherosclerosis 2009 May 204 (1): 191-5. Pruissen D M O, Kappelle L J, Rosendaal F R, Algra A, |
|
Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2-Center prospective cohort study.
American heart journal 2009 May 157 (5): 908-12. Suh Jung-Won, Baek Sang-Hong, Park Jin-Shik, Kang Hyun-Jae, Chae In-Ho, Choi Dong-Ju, Park Hun-Jun, Kim Pum-Joon, Seung Ki-Bae, Kim Hyo-S |
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
PLoS genetics 2009 Mar 5 (3): e1000433. Takeuchi Fumihiko, McGinnis Ralph, Bourgeois Stephane, Barnes Chris, Eriksson Niclas, Soranzo Nicole, Whittaker Pamela, Ranganath Venkatesh, Kumanduri Vasudev, McLaren William, Holm Lennart, Lindh Jonatan, Rane Anders, Wadelius Mia, Deloukas Pan |
|
VKORC1 genetic polymorphism and risk of venous thromboembolism in postmenopausal women: new findings and metaanalysis.
Journal of thrombosis and haemostasis : JTH 2009 Mar . Verstuyft C, Canonico M, Bouaziz E, Guiochon-Mantel A, Scarabin PY |
|
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
Pharmacogenomics 2009 Feb 10 (2): 261-6. Borgiani Paola, Ciccacci Cinzia, Forte Vittorio, Sirianni Elisabetta, Novelli Lucia, Bramanti Placido, Novelli Giusep |
|
A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
Journal of applied genetics 2009 50 (4): 399-403. Stepien E, Branicka A, Ciesla-Dul M, Undas |
|
VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Pharmacogenomics 2008 Nov 9 (11): 1631-8. Markatos Christos N, Grouzi Elissavet, Politou Marianna, Gialeraki Argyri, Merkouri Efrosyni, Panagou Ioannis, Spiliotopoulou Ioanna, Travlou Ant |
|
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
Clinica chimica acta; international journal of clinical chemistry 2008 Oct 396 (1-2): 76-9. Wang Ting-Liang, Li Hong-Lei, Tjong Wen-Ye, Chen Qian-Su, Wu Guan-Sheng, Zhu Hai-Tao, Hou Zi-Shan, Xu Shu, Ma Sheng-Jun, Wu Madeline, Tai Sus |
|
Single nucleotide polymorphisms in the VKORC1 gene and the risk of stroke in the Southern German population.
Thrombosis and haemostasis 2008 Oct 100 (4): 614-7. Arnold Marie-Luise, Lichy Christoph, Werner Inge, Radbruch Alexander, Wagner Simone, Grond-Ginsbach Casp |
|
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Clinical pharmacology and therapeutics 2008 Sep 84 (3): 326-31. Gage B F, Eby C, Johnson J A, Deych E, Rieder M J, Ridker P M, Milligan P E, Grice G, Lenzini P, Rettie A E, Aquilante C L, Grosso L, Marsh S, Langaee T, Farnett L E, Voora D, Veenstra D L, Glynn R J, Barrett A, McLeod H |
|
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Thrombosis and haemostasis 2008 Aug 100 (2): 229-39. Meckley Lisa M, Wittkowsky Ann K, Rieder Mark J, Rettie Allan E, Veenstra David |
|
Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Clinical pharmacokinetics 2008 47 (9): 565-94. Stehle Simone, Kirchheiner Julia, Lazar Andreas, Fuhr U |
|
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Pharmacogenomics 2007 Nov 8 (11): 1545-50. Borgiani Paola, Ciccacci Cinzia, Forte Vittorio, Romano Silvia, Federici Giorgio, Novelli Giusep |
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 15, 2019
- Content source: